Please wait while the formulary information is being retrieved.
FLUDARABINE PHOSPHATE (FLUDARABINE PHOSPHATE)
- Progressive chronic lymphocytic leukemia
- Fludarabine Iv
- Fludarabine Intravenous Solution
- Fludarabine Intravenous Powder For Solution
- By Indication
50 mg/2 mL intravenous solution
- Dosage information is not available
fludarabine 50 mg/2 mL intravenous solution
- Dosage information is not available
fludarabine 50 mg intravenous solution
- Dosage information is not available
Follicular lymphoma
- Infuse 30 mg/m2 by intravenous route once daily for 48 hours
- Infuse 25 mg/m2 by intravenous route once daily
- Infuse 25 mg/m2 by intravenous route once daily for 3 days
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactating mother
- Progressive multifocal leukoencephalopathy
- Severe renal impairment
Contraindicated
- Acquired factor VIII deficiency disease
- Acquired hemolytic anemia
- Acute confusion
- Acute decompensated heart failure
- Anemia
- Autoimmune hemolytic anemia
- Autoimmune thrombocytopenia
- Bacterial infection
- Bone marrow depression
- Coma
- Evans syndrome
- Fungal infection
- Herpes zoster
- Hypersensitivity pneumonitis
- Idiopathic thrombocytopenic purpura
- Interstitial pneumonitis
- Neutropenic disorder
- Optic neuritis
- Optic neuropathy
- Pancytopenia
- Pregnancy
- Renal disease with mild to moderate impairment
- Seizure disorder
- Severe infection
- Urate renal calculi
Severe
Moderate
- Abnormal hepatic function tests
- Cardiac arrhythmia
- Edema
FLUDARABINE PHOSPHATE (FLUDARABINE PHOSPHATE)
- Progressive chronic lymphocytic leukemia
- Anemia
- Edema
- Infection
- Neutropenic disorder
- Pain
- Pneumonia
- Thrombocytopenic disorder
- Chills
- Cough
- Diarrhea
- Fatigue
- Fever
- General weakness
- Malaise
- Nausea
- Skin rash
- Vomiting
More Frequent
Severe
Less Severe
- Acute confusion
- Agitation
- Blurred vision
- Peripheral neuropathy
- Stomatitis
- Anorexia
- Headache disorder
- Myalgias
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acidosis
- Acquired coagulation factor inhibitor disorder
- Acute respiratory distress syndrome
- Autoimmune hemolytic anemia
- Coma
- Crystalluria
- Evans syndrome
- Gastrointestinal hemorrhage
- Hearing loss
- Hematuria
- Hemorrhagic cystitis
- Hyperkalemia
- Hyperphosphatemia
- Hyperuricemia
- Hypocalcemia
- Pancytopenia
- Progressive multifocal leukoencephalopathy
- Pulmonary fibrosis
- Pulmonary hemorrhage
- Pulmonary infiltrates
- Renal failure
- Seizure disorder
- Severe bone marrow depression
- Sudden visual loss
- Thrombotic thrombocytopenic purpura
Less Severe
- Alopecia
- Dyspnea
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Fludarabine (Inj)
Risk of bone marrow suppression, thrombocytopenia, fever, chills, asthenia, rash, nausea, vomiting, diarrhea, and infection. Data insufficient to establish efficacy.
- 1 Day – 18 Years
- Risk of bone marrow suppression, thrombocytopenia, fever, chills, asthenia, rash, nausea, vomiting, diarrhea, and infection. Data insufficient to establish efficacy.
Fludarabine
- Severity Level:
D
- Additional Notes:
Contraindicated
Fludarabine
Potential for serious adverse effects on infant.
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Potential for serious adverse effects on infant. |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Fludarabine
Renal-Patients with moderate impairment of renal function (CrCl=30-70 mL/min/1.73 m2) should have their fludarabine dose reduced by 20% and be monitored closely.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- This medication may cause certain severe blood and bone marrow problems (low red blood cells/white blood cells/platelets, hemolytic anemia). These problems can decrease your body's ability to prevent/stop bleeding, fight infection, or carry enough oxygen in your blood. Tell your doctor right away if you develop easy bleeding/bruising, unusual tiredness, fast/pounding heartbeat, pale/bluish skin color, or signs of infection (e.g., fever, chills, persistent sore throat).<br /><br /> Fludarabine may rarely cause severe (sometimes fatal) central nervous system problems. Symptoms may not occur until weeks after your last treatment. Tell your doctor right away if you notice any vision changes, seizures, agitation, confusion, or numbness/tingling.<br /><br /> Do not use fludarabine with pentostatin (deoxycoformycin). Use of these 2 medications together has caused fatal lung problems.
| Progressive chronic lymphocytic leukemia | |
| C91.1 | Chronic lymphocytic leukemia of b-cell type |
| C91.10 | Chronic lymphocytic leukemia of b-cell type not having achieved remission |
| C91.12 | Chronic lymphocytic leukemia of b-cell type in relapse |
| 0-9 | A-Z |
|---|---|
| C91.1 | Chronic lymphocytic leukemia of b-cell type |
| C91.10 | Chronic lymphocytic leukemia of b-cell type not having achieved remission |
| C91.12 | Chronic lymphocytic leukemia of b-cell type in relapse |
Formulary Reference Tool